ReviewPrzeglad gastroenterologiczny2023
Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review.
Review in Przeglad gastroenterologiczny, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Tissue-Specific Isolation of Hepatocyte Extracellular Vesicles From Human Plasma Enables Tissue-Resolved Proteomic and miRNA Profiling.Journal of extracellular vesicles · 2026Article
- Review
- PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes.Frontiers in medicine · 2026Article
- Safety, Pharmacokinetics, Translational and Molecular Mechanistic Insights on the Prostate Cancer Recurrence Suppressor Pseurotin A.Molecules (Basel, Switzerland) · 2025Article
- The Role of the Liver in the Pathophysiology of PCOS: A Literature Review.Biomolecules · 2025Review
- Review
- PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker.GeroScience · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.